A Reversal for Durect Corporation (NASDAQ:DRRX) Is Not Near. The Stock Has Rise in Shorts

September 20, 2017 - By Hazel Jackson

 A Reversal for Durect Corporation (NASDAQ:DRRX) Is Not Near. The Stock Has Rise in Shorts

Investors sentiment increased to 1.24 in 2016 Q4. Its up 0.04, from 1.2 in 2016Q3. It improved, as 14 investors sold DURECT Corporation shares while 19 reduced holdings. 14 funds opened positions while 27 raised stakes. 68.34 million shares or 4.24% more from 65.56 million shares in 2016Q3 were reported.
Brown Advisory holds 60,000 shares or 0% of its portfolio. Citigroup holds 0% or 127,351 shares in its portfolio. Amer Group Incorporated holds 0% in DURECT Corporation (NASDAQ:DRRX) or 72,579 shares. 683 Mngmt Ltd Co stated it has 2.64 million shares or 0.25% of all its holdings. Schwab Charles Inv reported 177,776 shares or 0% of all its holdings. Amalgamated Savings Bank invested 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX). Royal Bancshares Of Canada stated it has 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX). First Eagle Investment Management Ltd Com has 22.43M shares for 0.08% of their portfolio. Blackrock Fund owns 4.03M shares. Bnp Paribas Arbitrage invested 0% in DURECT Corporation (NASDAQ:DRRX). Citadel Advsr Llc has invested 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX). 25,769 were reported by Principal Gp Incorporated. Susquehanna International Grp Inc Llp has 210,921 shares for 0% of their portfolio. Credit Suisse Ag has 0% invested in DURECT Corporation (NASDAQ:DRRX) for 54,163 shares. Blume Capital Management reported 6,000 shares.

The stock of Durect Corporation (NASDAQ:DRRX) registered an increase of 20.42% in short interest. DRRX’s total short interest was 2.02M shares in September as published by FINRA. Its up 20.42% from 1.67M shares, reported previously. With 329,700 shares average volume, it will take short sellers 6 days to cover their DRRX’s short positions. The short interest to Durect Corporation’s float is 1.67%.

It closed at $1.63 lastly. It is down 7.89% since September 20, 2016 and is uptrending. It has underperformed by 8.81% the S&P500.

Durect Corporation is a biopharmaceutical firm with research and development programs. The company has market cap of $239.61 million. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. It currently has negative earnings. The Company’s other product candidates include POSIMIR , REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR opioid (hydromorphone) and SABER ophthalmic.

DURECT Corporation (NASDAQ:DRRX) Ratings Coverage

Among 3 analysts covering Durect (NASDAQ:DRRX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Durect had 4 analyst reports since April 25, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, July 12 by Stifel Nicolaus. The firm has “Buy” rating by H.C. Wainwright given on Monday, August 14. The firm earned “Buy” rating on Friday, June 23 by H.C. Wainwright. The stock has “Buy” rating by Rodman & Renshaw on Monday, April 25.

More notable recent DURECT Corporation (NASDAQ:DRRX) news were published by: Prnewswire.com which released: “DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development” on September 20, 2017, also Prnewswire.com with their article: “DURECT and Sandoz have Signed a $293 Million Development and Commercialization …” published on May 08, 2017, Prnewswire.com published: “DURECT Corporation Announces Fourth Quarter and Full Year 2016 Financial …” on March 14, 2017. More interesting news about DURECT Corporation (NASDAQ:DRRX) were released by: Prnewswire.com and their article: “DURECT Corporation Announces Update on DUR-928 Development Program” published on January 30, 2017 as well as Prnewswire.com‘s news article titled: “DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings …” with publication date: February 24, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.